- Previous Close
5.22 - Open
5.22 - Bid 5.21 x 3200
- Ask 5.25 x 700
- Day's Range
5.09 - 5.39 - 52 Week Range
1.58 - 19.95 - Volume
932,817 - Avg. Volume
1,428,587 - Market Cap (intraday)
358.506M - Beta (5Y Monthly) -0.70
- PE Ratio (TTM)
-- - EPS (TTM)
-3.83 - Earnings Date Feb 20, 2025 - Feb 24, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.50
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
amylyx.comRecent News: AMLX
View More
Performance Overview: AMLX
Trailing total returns as of 11/20/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AMLX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AMLX
View MoreValuation Measures
Market Cap
357.82M
Enterprise Value
125.99M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.82
Price/Book (mrq)
1.82
Enterprise Value/Revenue
0.64
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-132.05%
Return on Assets (ttm)
-43.44%
Return on Equity (ttm)
-84.43%
Revenue (ttm)
196.48M
Net Income Avi to Common (ttm)
-259.47M
Diluted EPS (ttm)
-3.83
Balance Sheet and Cash Flow
Total Cash (mrq)
234.4M
Total Debt/Equity (mrq)
1.31%
Levered Free Cash Flow (ttm)
-78.9M
Research Analysis: AMLX
View MoreCompany Insights: AMLX
AMLX does not have Company Insights
Research Reports: AMLX
View MoreDaily – Vickers Top Buyers & Sellers for 09/06/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 04/03/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 03/30/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 03/24/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.